Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 20.78
-0.12 (-0.57%)
Feb 13, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Revenue
Nanjing Vazyme Biotech had revenue of 346.18M CNY in the quarter ending September 30, 2025, with 2.84% growth. This brings the company's revenue in the last twelve months to 1.34B, down -4.15% year-over-year. In the year 2024, Nanjing Vazyme Biotech had annual revenue of 1.38B with 7.15% growth.
Revenue (ttm)
1.34B
Revenue Growth
-4.15%
P/S Ratio
6.15
Revenue / Employee
468.92K
Employees
2,754
Market Cap
8.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.38B | 91.91M | 7.15% |
| Dec 31, 2023 | 1.29B | -2.28B | -63.97% |
| Dec 31, 2022 | 3.57B | 1.70B | 90.99% |
| Dec 31, 2021 | 1.87B | 304.17M | 19.44% |
| Dec 31, 2020 | 1.56B | 1.30B | 482.92% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.83B |
| Suzhou Fengbei Biotech Stock | 2.81B |
| Chengdu Kanghua Biological Products | 1.21B |
| Shanghai Medicilon | 1.08B |
| Wuhan Keqian Biology Co.,Ltd | 1.01B |
| Jiangxi Fushine Pharmaceutical | 970.32M |
| Acrobiosystems | 794.52M |
| Daan Gene | 765.48M |